Cancer

Lunit highlights analysis of Triumph mCRC trial outcomes
By LabPulse.com staff writers
Lunit is highlighting new findings from colorectal cancer treatment research using the Lunit SCOPE HER2 analyzer, the SCOPE IO tumor microenvironment analyzer, and artificial intelligence.
January 23, 2025
(D and E) Representative patients from the Triumph study demonstrating AI-HER2 3+ with low (C, 18.1%) and high (D, 97.4%) AI-H3. The left panels show the original WSIs, and the right panels show the WSIs processed by the AI analyzer. Tumor cells are color-coded according to HER2 staining intensity. (Blue: HER2-negative tumor cells, green: HER2 1+ tumor cells, yellow: HER2 2+ tumor cells, red: HER2 3+ TC). The green-shaded area indicates the cancer area. Images courtesy of Imai et al. Licensed under CC BY 4.0.
Scopio Labs expands Siemens alliance to drive digital hematology
By LabPulse.com staff writers
Scopio Labs and Siemens Healthineers have expanded their alliance to include the global distribution of Scopio's Full-Field Bone Marrow Aspirate application in aiding the diagnosis of blood disorders.
January 14, 2025
Business Handshake Intelligence Social
Roche gets FDA 510(k) clearance for B-cell lymphoma assay
By LabPulse.com staff writers
Roche has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its assay designed to aid in the diagnosis of B-cell lymphoma.
January 13, 2025
Roche Brand Media Library Image 2024 Social
NEC, Biomy collaborate on AI-driven digital pathology platform
By LabPulse.com staff writers
NEC and Biomy have formed a joint marketing partnership to develop and expand artificial intelligence (AI)-based analytical digital pathology platforms.
January 10, 2025
Business Handshake Intelligence Social
Oxford University team develops early-detection multicancer test
By LabPulse.com staff writers
Oxford University researchers have developed a promising liquid biopsy test that uses machine learning to detect six forms of cancer in their earliest stages.
January 9, 2025
Cancer Cell Microenvironment Social
Myriad expands scope of whole genome sequencing-based MRD projects
By LabPulse.com staff writers
The goal of the studies is to generate evidence that supports national guideline inclusion and healthcare provider adoption.
January 7, 2025
Dna Cancer Cell Social
Geneoscopy raises $105M for CRC, IBD test drive
By LabPulse.com staff writers
Geneoscopy has raised $105 million in a Series C funding round led by Bio-Rad Laboratories.
January 8, 2025
Colorectal Cancer Social
Sysmex America, DiaCarta highlight FIT CRC screening tests
By LabPulse.com staff writers
Developments that may signal increased fecal immunochemical testing in colorectal cancer screening worldwide in 2025.
January 6, 2025
Colorectal Cancer Social
Quest to provide services for Mainz Biomed CRC test clinical trials
By LabPulse.com staff writers
Mainz Biomed has made an agreement with Quest Diagnostics in which Quest will support the commercialization of Mainz Biomed’s next-generation ColoAlert colorectal cancer (CRC) screening test.
December 19, 2024
Colorectal Cancer Social
USPSTF proposes new cervical cancer screening guidelines
By Liz Carey
While some signals abroad favor HPV DNA testing, USPSTF stays focused on cervical cytology alone or in combination.
December 11, 2024
Pathology Pap Smear Cervical
Gilead, Tubulis to collaborate on ADC program
By LabPulse.com staff writers
Gilead and biotech firm Tubulis have forged an exclusive option and license agreement to discover and develop an antibody-drug conjugate (ADC) against an undisclosed solid tumor target.
December 3, 2024
Cancer Cell Microenvironment Social
Jury awards Guardant nearly $293M in lawsuit against Natera
By LabPulse.com staff writers
A federal jury in the U.S. District Court for the Northern District of California ruled in favor of Guardant Health in a lawsuit the company filed against Natera in May 2021.
November 26, 2024
Gavel Money Lawsuit Social
Page 1 of 100
Next Page